Registration Dossier

Administrative data

Description of key information

One key acute oral toxicity study is available.  The study was conducted according to OECD Guideline 401 and used rat Sprague-Dawley rats as the test species.  The dose-level of 2000 mg/kg of N-[3-(dimethylamino)propyl]-C18 unsaturated-alkylamide (unsaturated C18) was estimated to be the oral median lethal dose, LD50 in rats. No studies are available for acute inhalation or dermal toxicity.

Key value for chemical safety assessment

Acute toxicity: via oral route

Link to relevant study records
Reference
Endpoint:
acute toxicity: oral
Type of information:
experimental study
Adequacy of study:
key study
Study period:
August 2002
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
other: GLP and test guideline compliant study with no deviations affecting study integrity/validity
Qualifier:
according to
Guideline:
OECD Guideline 401 (Acute Oral Toxicity)
Deviations:
yes
Remarks:
The temperature recorded in the animal room was sometimes outside of the target ranges specified in the study plan but it was not considered to have compromised the validity or integrity of the study.
Qualifier:
according to
Guideline:
EU Method B.1 (Acute Toxicity (Oral))
Deviations:
yes
Remarks:
see above
GLP compliance:
yes (incl. certificate)
Limit test:
yes
Species:
rat
Strain:
Sprague-Dawley
Sex:
male/female
Details on test animals and environmental conditions:
TEST ANIMALS
- Source: Janvier, Le Genest-Saint-Isle, France
- Age at study initiation: 6 weeks old
- Weight at study initiation: 187+/-13g for the males and 177+/-10g for the females
- Fasting period before study: overnight period of approximately 18 hours before dosing but free access to water ; food was given back approximatety 4 hours after administration of the test item.
- Housing: polycarbonate cages with stainless steel lid (48cmx27cmx20cm)
- Diet : free access to A04C pelleted diet (UAR, Villemoisson, Epinay sur Orge, France)
- Water : drinking water filtered by a FG Millipore membrane (0.22 micron), ad libitum
- Acclimation period: at least 5 days before the beginning of the study


ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22+/-2
- Humidity (%): 30 to 70
- Air changes (per hr): 12 cycles /hour of filtered, non recycled air
- Photoperiod (hrs dark / hrs light): 12h/12h
Route of administration:
oral: gavage
Vehicle:
unchanged (no vehicle)
Doses:
2000mg/kg
No. of animals per sex per dose:
5 males and 5 females
Control animals:
no
Details on study design:
- Duration of observation period following administration: 22 days
- Clinical signs and mortality : frequent observation during the hours following administration of the test item, then at least once a day until day 15 and 22.
- Body weight : just before administration of the test item on day 1 and then on days 8, 15 and 22.
- Macroscopic necropsy examination : yes
Sex:
male/female
Dose descriptor:
LD50
Effect level:
> 2 000 mg/kg bw
Mortality:
Three out of five males and 1/5 female died during the study between day 2 and day 8
Clinical signs:
Hypoactivity or sedation, piloerection, dyspnea, hypersalivation and swollen abdomen were recorded in these animals prior to death as well as in the surviving animals from day 1.
Recovery was complete in almost all surviving males on day 12 but piloerection, dyspnea and swollen abdomen persisted in one male up to day 20.
Body weight:
A reduced weight gain was seen in one of the surviving males between day 1 and day 8. The overall body weight gain of the other animals was similar to that of historical control animals.
Gross pathology:
Macroscopic examination of the main organs of the animals revealed no apparent abnormalities.
Interpretation of results:
not classified
Remarks:
Migrated information Criteria used for interpretation of results: EU
Conclusions:
Under our experimental conditions, the oral LD50 of the test substance is higher than 2000 mg/kg in rats.
Executive summary:

The acute oral toxicity of the test substance was evaluated in rats according to OECD (No. 401, 24thFebruary 1987) and EC (92/69/EEC, B.1, 31stJuly 1992) guidelines.

The study was conducted in compliance with the principles of Good Laboratory Practice Regulations.

The test substance was administered by oral route (gavage) to one group of ten fasted Sprague-Dawley rats (five males and fives females).

The test substance was administered undiluted at the dose of 2000 mg/kg, taking into consideration that its specific gravity was 0.896 g/ml.

Clinical signs, mortality, and body weight gain were checked for a period of up to 21 days following the single administration of the test item.

All animals were subjected to necropsy.

Three out of five males and 1/5 female died during the study between day 2 and day 8. Hypoactivity or sedation, piloerection, dyspnea, hypersalivation and swollen abdomen were recorded in these animals prior to death as well as the surviving animals from day 1.

Recovery was complete in almost all surviving males on day 12 but piloerection, dyspnea and swollen abdomen persisted in one male up to day 20.

A reduced weight gain was seen in one of the surviving males between day 1 and day 8. The overall body weight gain of the other animals was similar to that of CIT historical control animals. No apparent abnormalities were observed at necropsy in any animals.

Under the experimental conditions, the oral LD50 of the test substance is higher than 2000 mg/kg in rats.

According to the classification criteria laid down in Council Directive 67/548/EEC (and subsequent adaptations), the test substance does not present a significant acute toxic risk of swallowed.
Endpoint conclusion
Endpoint conclusion:
adverse effect observed
Dose descriptor:
LD50
2 000 mg/kg bw
Quality of whole database:
The study is Klimisch 1 and GLP compliant

Acute toxicity: via inhalation route

Endpoint conclusion
Endpoint conclusion:
no study available

Acute toxicity: via dermal route

Endpoint conclusion
Endpoint conclusion:
no study available

Additional information

Acute oral toxicity

One key acute oral toxicity study is available. The study was conducted according to OECD Guideline 401 in compliance with the principles of Good Laboratory Practice Regulations.

The test substance was administered by oral route (gavage) to one group of ten fasted Sprague-Dawley rats (five males and five females).The test substance was administered undiluted at the dose of 2000 mg/kg, taking into consideration that its specific gravity was 0.896 g/ml.

Clinical signs, mortality, and body weight gain were checked for a period of up to 21 days following the single administration of the test item.All animals were subjected to necropsy.

Three out of five males and 1/5 female died during the study between day 2 and day 8. Hypoactivity or sedation, piloerection, dyspnea, hypersalivation and swollen abdomen were recorded in these animals prior to death as well as the surviving animals from day 1. Recovery was complete in almost all surviving males on day 12 but piloerection, dyspnea and swollen abdomen persisted in one male up to day 20. A reduced weight gain was seen in one of the surviving male between day 1 and day 8. The overall body weight gain of the other animals was similar to that of historical control animals. No apparent abnormalities were observed at necropsy in any animals.

Under the experimental conditions, the oral LD50 of the test substance is higher than 2000 mg/kg in rats. According to Regulation EC No. 2172/2008,

the test substance does not present a significant acute toxic risk of swallowed.

Acute inhalation toxicity :

There is no study available for acute inhalation toxicity for N-[3-(dimethylamino)propyl]-C18 unsaturated-alkylamide (unsaturated C18). REACH guidance R.7.a, chapter. 7.4 Acute toxicity, indicates that in principle no inhalation studies are needed when vapour pressure < 0.1 Pa at 20°C or particle size > 100 µm. N-[3-(dimethylamino)propyl]-C18 unsaturated-alkylamide (unsaturated C18) is a liquid with a vp around 1.78 10-7Pa at 25°C (EPI suite estimation). Also the use of this substance will not result in aerosols, particles or droplets of an inhalable size, so exposure to humans via the inhalatory route will be unlikely to occur.

 

Acute dermal toxicity :

No acute dermal study is available. The substance is classified as corrosive to skin and testing for acute toxicity is therefore not needed according to REACH regulation (EC) 1907/2006 (Annex VIII, point 8.5, column 2). Use and handling of the pure substance is only industrial and professional (formulation), and the classification of the substance as corrosive requires risk management methods which eliminate the risk of acute systemic toxicity by dermal route.


Justification for selection of acute toxicity – oral endpoint
Only one available study.

Justification for selection of acute toxicity – inhalation endpoint
Exposure to humans via the inhalatory route is unlikely to occur.

Justification for selection of acute toxicity – dermal endpoint
Study scientifically unjustified

Justification for classification or non-classification

Under the experimental conditions of the study, the oral median lethal dose, LD50 in rats for N-[3-(dimethylamino)propyl]-C18 unsaturated-alkylamide (unsaturated C18), was estimated to be higher than 2000 mg/kg. According to regulation 67-548 EEC and CLP regulation(EC) N° 1272/2008, the test substance should not be classified for oral acute toxicity.

Dermal systemic toxicity is expected to be similarly low, while corrosive properties will limit likelihood of exposures.

Related to low vapour pressure (~1.78 10 -7Pa), exposure via inhalation is unlikely.

No classification STOT-SE Cat.3 needed as the active substance is not structurally related to any known class of neurotoxic chemicals and no indications of specific neurotoxicity were observed from the available repeated toxicity studies.

Also available studies indicate that there is no need of a classification for aspiration hazard.